News | PET Imaging | June 29, 2018

SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

2018 winner uses PSMA PET imaging to demonstrate high response rates of metastatic castrate-resistant prostate cancer patients to LuPSMA therapy

SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

June 29, 2018 — In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), researchers reported on a phase II prospective trial. Using gallium-68 positron emission tomography (PET) imaging, men who had exhausted conventional therapies were screened. Those with high PSMA-expression proceeded to 177Lu-PSMA617 (LuPSMA) therapy and experienced high response rates, which is clearly demonstrated in the PSMA PET imaging figure selected as the 2018 SNMMI Image of the Year.

Each year, SNMMI chooses an image that exemplifies the most promising advances in the field of nuclear medicine and molecular imaging. The state-of-the-art technologies captured in these images demonstrate the capacity to improve patient care by detecting disease, aiding diagnosis, improving clinical confidence and providing a means of selecting appropriate treatments. This year, the SNMMI Henry N. Wagner Jr. Image of the Year was chosen from more than 2,200 abstracts submitted to the meeting and voted on by reviewers and the society leadership.

The 2018 Image of the Year goes to a team of researchers at the Peter MacCallum Cancer Centre in Melbourne, Australia. The image demonstrates exceptional responses in a series of patients who received LuPSMA therapy after other treatments stopped working. In each patient, the extent of tumor spread before and after treatment is visualized with clarity using PSMA PET. These patients experienced improved quality of life, including reduction of pain, and correlated with marked reduction of prostate specific antigen (PSA), a blood tumor marker.

"This work reflects an appreciation for all the basic science and translation work that has been performed by many groups over a long period of time to develop prostate-specific membrane antigen (PSMA) theranostics as a paradigm-changing practice for improving patient outcomes,” explained Prof. Michael Hofman of the Peter MacCallum Cancer in Melbourne, Australia. “These images tell a story about exceptional responses observed in patients who had progressed after standard therapies. They match striking improvements in patient quality of life. With further research, we look forward to seeing nuclear medicine evolve as a key specialty and standard-of-care in cancer management." He added, "I would also like to extend thanks to ANSTO, Australia's producer of no-carrier-added Lutetium-177, and Endocyte, which produces PSMA; they helped make this study possible."

Umar Mahmood, M.D., Ph.D., chair of the SNMMI Scientific Program Committee, noted, “The last decade has seen a blossoming of theranostics to treat tumors with molecularly-guided radiotherapy. The expansion of patients benefiting from this approach is remarkable, and it is wonderful to know that this effort is being led by nuclear medicine physicians and scientists.”

Mahmood stated, “Prostate cancer, which affects millions of men around the world, can be painful and deadly in the metastatic setting. This phase II prospective study by Michael Hofman and colleagues clearly shows the benefit to men with castrate-resistant prostate cancer treated with a beta emitter targeting PSMA when their tumors expressed PSMA. It is gratifying to see the benefit of the approach both rigorously and objectively demonstrated in this trial, in terms of improvement in disease burden and improvement in the pain severity the men suffered.”

For more information: www.snmmi.org

Related Content

Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...